Supplementary Figure S3 from A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer | Synapse
June 3, 2024Open Access
Supplementary Figure S3 from A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Figure S3: Mean baseline cortisol calculated in twenty (20) patients at day 1 and day 28